The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers-Reference-Cited by-同舟云学术

The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

Published:2007 Issue:9 Volume:46 Page:787-802
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clinical Pharmacokinetics

Author:

He Yan-Ling,Sadler Brian M,Sabo Ron,Balez Sebastien,Wang Yibin,Campestrini Joelle,Laurent Aziz,Ligueros-Saylan Monica,Howard Dan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference3 articles.

1. The GLP‐1 system as a therapeutic target

2. Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment;Pharmaceuticals;2024-07-10

2. In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine;Biopharmaceutics & Drug Disposition;2024-02-24

3. A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations;Expert Opinion on Drug Metabolism & Toxicology;2023-11-26

4. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants;Journal of Medicinal Chemistry;2023-08-30

5. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition;Acta Pharmaceutica Sinica B;2022-11